Neurodegenerative Diseases and the Human Microbiota

Print version:

NEURODEGENERATIVE DISEASES AND THE HUMAN MICROBIOTA

COPYRIGHT PAGE

FOREWORD

INDEX

CHAPTER 1. INTRODUCTION TO THE MICROBIAL WORLD

1.1. A NEW CONCEPT IN MICROBIAL PATHOLOGY

1.2. CLASSIFICATION OF MICROORGANISMS

1.2.1. CLASSIFICATION OF BACTERIA AND ARCHAEOBACTERIA

1.2.2. CLASSIFICATION OF FUNGI

1.2.3. CLASSIFICATION OF VIRUSES

1.3. SOME MICROORGANISMS OF INTEREST

1.3.1. BACTERIA

1.3.2. FUNGI

1.4. MICROBIAL TOXINS

REFERENCES

CHAPTER 2. THE HUMAN MICROBIOTA

2.1. BASIC NOTIONS ABOUT THE MICROBIOTA

2.2. MICROBIAL INTERACTIONS 2.3. ACQUISITION OF THE MICROBIOTA IN THE FIRST MONTHS OF LIFE

2.4. THE MICROBIOTA IN THE PRE-URBAN ERA

2.5. INTERNAL TISSUES MAY CONTAIN MICROBES

REFERENCES

CHAPTER 3. NEURODEGENERATIVE DISEASES

3.1. INTRODUCTION

3.2. THE NEW PARADIGM: POLYMICROBIAL INFECTIONS AS CAUSATIVE AGENTS OF (...)

3.3. ALZHEIMER'S DISEASE

3.3.1. MICROBIAL INFECTIONS IN ALZHEIMER'S DISEASE

3.3.2. STARCHY BODIES (CORPORA AMYLACEA) IN THE BRAINS OF PATIENTS WITH (...)

3.3.3. ENDOMYCOSOMES

3.3.4. ARGUMENTS SUPPORTING MICROBIAL INFECTIONS AS THE CAUSE OF (...)

3.4. PARKINSON'S DISEASE 3.4.1. INVOLVEMENT OF MICROBIAL AGENTS IN PARKINSONŚ DISEASE

3.4.2. FACTS IN FAVOR OF THE MICROBIAL ETIOLOGY OF PARKINSON'S DISEASE

3.5. HUNTINGTON'S DISEASE

3.5.1. INVOLVEMENT OF MICROORGANISMS IN THE ETIOLOGY OF HUNTINGTON'S DISEASE

3.5.2. COMMENTS ON THE INVOLVEMENT OF INFECTIONS IN HUNTINGTON'S DISEASE

3.6. AMYOTROPHIC LATERAL SCLEROSIS

3.6.1. SEARCH FOR INFECTIONS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS

3.6.2. POLYMICROBIAL INFECTIONS EXPLAIN THE CLINICAL FINDINGS IN PATIENTS (...)

3.7. MULTIPLE SCLEROSIS 3.7.1. PRESENCE OF MYCOSES AND BACTERIAL INFECTIONS IN THE CNS OF PATIENTS (...)

3.7.2. CONSIDERATIONS ON THE NEW PROPOSAL FOR POLYMICROBIAL INFECTIONS IN (...)

REFERENCES

REFERENCES FROM OUR GROUP

CHAPTER 4. OTHER HUMAN DISEASES

4.1. OTHER NEUROLOGICAL DISEASES

4.1.1. AUTISM

4.1.2. SCHIZOPHRENIA

4.1.3. EPILEPSY

4.1.4. MYALGIC ENCEPHALOMYELITIS

4.2. AUTOIMMUNE DISEASES

4.2.1. SYSTEMIC LUPUS ERYTHEMATOSUS

4.2.2. RHEUMATOID ARTHRITIS

4.2.3. INFLAMMATORY BOWEL DISEASE

4.2.4. SYSTEMIC SCLEROSIS

4.3. ALLERGIC ASTHMA

4.4. CARDIOVASCULAR DISEASES 4.5. CANCER

4.6. RARE DISEASES

4.7. OPHTHALMIC DISEASES

4.7.1. EYE CATARACTS

4.7.2. GLAUCOMA

4.7.3. SJOGREN'S SYNDROME. DRY EYE

4.7.4. RETINOPATHIES. AZOOR

REFERENCES

CHAPTER 5. DIAGNOSIS AND TREATMENT

5.1. DIAGNOSIS

5.1.1. FUNGAL GROWTH FROM HUMAN SAMPLES

5.1.2. FUNGAL DNA ANALYSIS

5.1.3. ANALYSIS OF FUNGAL PROTEINS

5.1.4. ANALYSIS OF FUNGAL POLYSACCHARIDES

5.1.5. ANALYSIS OF FUNGAL METABOLITES

5.1.6. DETECTION OF EMERGING INFECTIONS

5.1.7. DETECTION OF RESISTANT MUTANTS

5.1.8. ANALYSIS OF THE RELATIONSHIP BETWEEN THE PATHOGEN AND THE HOST